PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies
London, UK, 24 March, 2022 PharmaVentures is pleased to announce that it acted as transaction advisor to Lausanne University Hospital (CHUV) and EPFL in Switzerland on their commercial terms related to the collaboration and licensing of their highly potent SARS-CoV-2...
PharmaVentures moves HQ to London to support its continued growth strategy
London, UK, 10 February 2022 PharmaVentures today announced it has moved its operational headquarters from Oxford to London as part of its continued strategic expansion. The company will retain its remaining operational and administrative functions at its new...
PharmaVentures and Shinhan Investment Corp sign Memorandum of Understanding to strengthen global collaboration for the Korean biopharma industry
Oxford, UK, 18 November 2021 PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group & Global Investment Banking Group (SHIC). This MOU was signed by Adrian...
PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio
Oxford, UK, 15 October 2021 PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio. This follows the recent announcement that IntoCell has established a research collaboration partnership...
PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar
Oxford, UK, 15 July 2021 PharmaVentures is pleased to announce that it is acting as advisor to Intocell on their ongoing collaboration agreement with Cellectar. This follows the announcement that Cellectar and Intocell have expanded their collaboration using...
PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM
Oxford, UK, 29 June 2021 PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert with respect to Spectral MD’s listing on London’s AIM on June 22nd. Adrian Dawkes, Managing Director at PharmaVentures, said: “Through our...
PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH
Oxford, UK, 03 March 2021 PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH. ERA Consulting is a leading strategic product development and regulatory consulting group serving the...
PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor
Oxford, UK, 24th November 2020 PharmaVentures today announced it has acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4. GPCR has signed an exclusive agreement with TaiGen Biotechnology...
PharmaVentures advises Novartis on the sale of its manufacturing facility in Barberà del Vallès to Siegfried Holding AG
Oxford, England, 5th October 2020. PharmaVentures Ltd (“PharmaVentures”) is pleased to announce that it was the corporate finance advisor to Novartis on the divestment of its manufacturing facility in Barberà del...
PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma.
Oxford, England, 6th September 2018 PharmaVentures Ltd (“PharmaVentures”) is pleased to announce that it acted as exclusive adviser to Vital Food Processors Ltd (“Vital Foods”), an agricultural science company founded in New Zealand, on an asset purchase...
PharmaVentures advises SalvaRx Group plc on the acquisition of SalvaRx Ltd by Portage Biotech Inc.
Oxford, UK, 20 August 2018 PharmaVentures Ltd. (“PharmaVentures”) is pleased to announce that it acted as an independent adviser to SalvaRx Group plc (SALV:LSE) (“SalvaRx”) and Portage Biotech, Inc (“Portage”), on the acquisition of its subsidiary SalvaRx Ltd by...
PharmaVentures Strengthens Its First-Class Strategy Consulting & Dealmaking Capabilities
PharmaVentures strengthens its first class healthcare strategy and dealmaking capabilities with the recruitment of a new Vice President, Ashley Cox. Ashley has built significant industry experience working directly for a number of pharmaceutical companies,...
PharmaVentures Capital Ltd advises Biosceptre International Ltd, a clinical stage oncology company, on its Series A private placement by Tuspark S&T
PharmaVentures Capital Limited is pleased to announce that it acted as adviser to Biosceptre International Limited (“Biosceptre”) for the successful Series A private placement from the Chinese conglomerate Tuspark Science & Technology Service Group (Tuspark)...
PharmaVentures advises IDT Australia on the divestment of CMAX clinical trial business to the Japanese company I’rom Group Co. Ltd.
OXFORD, UK, October 28th, 2016 PharmaVentures is pleased to announce that it acted as adviser to IDT Australia Limited for the successful divestment of CMAX, a dedicated clinical trials business, to the Japanese healthcare company I'rom Group Co. Ltd. for a...
PharmaVentures advises the Baylor Scott & White Research Institute on collaboration with Abzena plc and creation of Denceptor Therapeutics
OXFORD, UK, July 27st, 2016PharmaVentures is pleased to announce that it acted as an adviser to the Baylor Scott & White Research Institute in connection with the creation of Denceptor Therapeutics Limited.Denceptor Therapeutics will develop immunotherapeutic...
PharmaVentures expands corporate advisory services through new UK Financial Conduct Authority (FCA) regulated firm
OXFORD, UK, July 21st, 2016 PharmaVentures is pleased to announce that today it has launched a new FCA regulated firm, Pharmaventures Capital Ltd which will carry out all future FCA regulated corporate finance related mandates. The new firm, which is 100% owned by...
PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today
OXFORD, UK, March 22nd, 2016. PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert adviser to 3Legs on its Reverse Takeover of SalvaRx. 3Legs Resources is an investment company that focuses on life sciences...
PharmaVentures advises Transgene on the sale of their biopharmaceutical manufacturing facility
OXFORD, UK, February 4th, 2016. PharmaVentures is pleased to announce that it acted as an advisor to Transgene on the sale of its biopharmaceutical manufacturing unit in Strasbourg, France, to the US company Advanced Bioscience Laboratories (ABL), Inc. Transgene...